{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nEmbodiment 5The antibody according to any one of embodiments 1-4, wherein said antibody binds to a prostate tumor cell with an affinity (KD) of at least about 5 nM when measured on live prostate tumor cells by FACS.\nEmbodiment 6The antibody of embodiment 5, wherein said antibody binds to a prostate tumor cell with an affinity (KD) of at least about 3 nM when measured on live prostate tumor cells by FACS."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "5", "unit": "nM"}, {"molecule_name": "antibody", "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "3", "unit": "nM"}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a specific molecule name, ID, or other identifier, a bioactivity metric, a specific numeric value for that metric, and a unit for that value."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAn antibody that \u201cdoes not exhibit significant cross-reactivity\u201d is one that will not appreciably bind to an undesirable entity (e.g., an undesirable proteinaceous entity), for example, in one embodiment, an antibody or antigen-binding portion thereof that specifically binds to CD46 CPP1 appreciably bind that CD46 CPP1 protein but will not significantly react with other molecules and non-CD46 proteins or peptides with an affinity of at least (KD equal to or less than) 10^\u22126 M, 10^\u22127 M, 10^\u22128 M, 10^\u22129 M, 10^\u221210 M, or 10^\u221211 M.\nIn one embodiment, the antibody or antigen binding portion thereof according to the present invention binds an antigen (e.g., CD46-CPP1) with an affinity (K_D) of 5 nM or better (i.e., or less) (e.g., 40 nM or 30 nM or 20 nM or 10 nM or less), as measured using a surface plasmon resonance assay or a cell binding assay.\nIn a particular embodiment, an antibody or antigen binding portion thereof according to the present invention binds CD46 CPP1 with an affinity (K_D) of 5 nM or better (e.g., 4 nM, 2 nM, 1.5 nM, 1.4 nM, 1.3 nM, 1 nM or less), as measured by a surface plasmon resonance assay or a cell binding assay.\nIn other embodiments, an antibody or antigen binding portion thereof binds an antigen (e.g., CD46 CPP1) with an affinity (K_D) of approximately less than 10^\u221210 M, or 100\u00d710^\u221211 M, or 10\u00d710^\u221211 M, or even lower using live prostate tumor cells by FACS."}
{"final_json": [{"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1 protein", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^\u22126", "unit": "M"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46-CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "5", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "5", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "4", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "2", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "1.5", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "1.4", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "1.3", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "1", "unit": "nM"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "<10^\u221210", "unit": "M"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "100\u00d710^\u221211", "unit": "M"}, {"molecule_name": "CD46 CPP1", "protein_target_name": "CD46 CPP1", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "K_D", "value": "10\u00d710^\u221211", "unit": "M"}]}
{"raw_mentions": "In certain embodiments the antibody binds to a prostate tumor cell with an affinity greater than (K<sub>D </sub>less than) about 5 nM when measured on live prostate tumor cells by FACS.\nIn certain embodiments the affinity is greater than (KD less than) about 1 nM, or at about 100 pM, or about 50 pM, or about 10 pM, or about 1 pM."}
{"final_json": [{"molecule_name": null, "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<5", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<1", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "100", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "50", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "prostate tumor cell", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "1", "unit": "pM"}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, bioactivity metrics, numeric values, and units as required."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a specific molecule name, ID, or other identifier, a bioactivity metric, a specific numeric value for that metric, and a unit for that value."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nMeasured on live tumor cells by FACS, the apparent KD for 2B10 is about 1-5 nM while for UA20 about 5-10 nM (FIG. 7)."}
{"final_json": [{"molecule_name": "2B10", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "1-5", "unit": "nM"}, {"molecule_name": "UA20", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "5-10", "unit": "nM"}]}
